NASDAQ:ADLR - Adolor Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started Previous CloseN/AToday's RangeN/A52-Week RangeN/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileChartEarningsFinancialsHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Adolor Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pain and pain-management products. ENTEREG (alvimopan) is the United States Food and Drug Administration (FDA) approved product. ENTEREG is indicated to accelerate upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis. The Company is conducting two Phase 2 clinical trials of ADL5945 to treat opioid-induced constipation (OIC), a condition that often results from long-term use of opioid analgesics in the management of chronic pain conditions. In addition, it is continuing development efforts on ADL7445, a second peripherally-acting mu opioid receptor antagonist, which is considered a back-up compound in its OIC program. The Company has completed Phase 1 clinical evaluation of ADL6906 (beloxepin). In December 2011, Cubist Pharmaceuticals, Inc. acquired Adolor Corporation. Receive ADLR News and Ratings via Email Sign-up to receive the latest news and ratings for ADLR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorN/A Current SymbolNASDAQ:ADLR Previous Symbol CUSIPN/A CIK1076167 Webhttp://www.adolor.com/ Phone+1-302-6587581Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Adolor (NASDAQ:ADLR) Frequently Asked Questions What is Adolor's stock symbol? Adolor trades on the NASDAQ under the ticker symbol "ADLR." Has Adolor been receiving favorable news coverage? News headlines about ADLR stock have trended neutral on Friday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Adolor earned a news impact score of 0.3 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. How do I buy shares of Adolor? Shares of ADLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Adolor's official website? The official website for Adolor is http://www.adolor.com/. How can I contact Adolor? Adolor's mailing address is 700 Pennsylvania Dr, EXTON, PA 19341-1129, United States. The biopharmaceutical company can be reached via phone at +1-302-6587581. MarketBeat Community Rating for Adolor (NASDAQ ADLR)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 44 (Vote Outperform)Underperform Votes: 33 (Vote Underperform)Total Votes: 77MarketBeat's community ratings are surveys of what our community members think about Adolor and other stocks. Vote "Outperform" if you believe ADLR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADLR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/24/2019 by MarketBeat.com StaffFeatured Article: Candlestick Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.